South Korea no longer plans to buy GlaxoSmithKline Plc’s H1n1 swine flu vaccine, Pandemrix, reports said quoting health ministry officials.
CMOs market to touch $33.7bn by 2014 from the current $22.2bn
Velaglucerase alfa, an enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, may hit the market soon.
Avastin, the much-hyped block-buster anti-cancer therapy from Roche has been rejected by as treatment against colorectal cancer.
Human Genome Sciences, Inc is seeking approval for albinterferon alfa-2b (Zalbin) for the treatment of chronic hepatitis C.
Gencaro (bucindolol hydrochloride) for the treatment of patients with chronic heart failure by ARCA bioharma Inc has been granted fast track designation by US FDA.